Products
At ImmuNova BioMed, we are redefining healthcare through cutting-edge research and advanced biotechnological solutions. Our product portfolio currently includes:
Nanovaccine Immunotherapy for Cancer
Product: NanoVax-Onco
Description: A personalized nanovaccine platform delivering tumor-specific antigens directly to dendritic cells. This approach enhances antigen presentation and activates cytotoxic T cells to target and destroy cancer cells.
Target Cancers: Colon, lung, breast, melanoma, pancreatic, and prostate cancers.
Stage: Pre-clinical and early-stage clinical trials.
Immunomodulators for Autoimmune Diseases
Product: NanoMod-AI
Description: A nanotechnology-based immunomodulator designed to regulate overactive immune responses in autoimmune diseases like rheumatoid arthritis, multiple sclerosis, and lupus. These nanoparticles target overactive immune cells while preserving overall immune function.
Focus: Precision-targeted immune modulation to reduce inflammation and tissue damage.
Stage: Early R&D, pre-clinical studies.
Nanovaccine Platform for Infectious Diseases
Product: NanoVax-Infect
Description: A flexible nanovaccine platform that adapts to emerging infectious diseases (e.g., COVID-19, influenza, novel viruses). Utilizing self-assembling nanoparticles, it delivers viral antigens to promote long-lasting immunity without traditional adjuvants.
Focus: Pandemic preparedness and vaccines for challenging infections.
Stage: Late pre-clinical, regulatory planning.
Combination Nanovaccine and Checkpoint Inhibitors
Product: NanoVax-Immune+
Description: Combines nanovaccines with checkpoint inhibitors (e.g., PD-1, CTLA-4 blockers) to enhance immune responses and overcome immune checkpoint suppression, enabling a comprehensive attack on tumor cells.
Stage: Proof-of-concept studies underway.
Innovative Solutions
At ImmuNova BioMed, we are redefining healthcare through cutting-edge research and advanced biotechnological solutions. Our product portfolio currently includes:
Precision Target Nanoparticles
Designed to combat cancer using photodynamic therapy while inducing a localized immunological response.
Peptides with Immunostimulatory Properties
Engineered to enhance the efficacy and performance of tumor-recognizing immune cells.
Personalized Cancer Vaccines
Nova Design-Based Checkpoint Block Mimetic Peptide Nanobody. Innovative molecules designed to block immune checkpoints, enhancing cancer immunotherapy outcomes.
Nova Design-Based Checkpoint Block Mimetic Peptide Nanobody
Innovative molecules designed to block immune checkpoints, enhancing cancer immunotherapy outcomes.
Technology Platform
At ImmuNova BioMed, we are redefining healthcare through cutting-edge research and advanced biotechnological solutions. Our product portfolio currently includes:
Nanoparticles for Precision Drug Delivery
ImmuNova BioMed’s proprietary nanoparticle delivery system optimizes the targeting and uptake of antigens, immune modulators, or drugs by the immune system. These biodegradable nanoparticles are designed for controlled release, maximizing therapeutic efficacy while minimizing side effects.
Self-Assembling Nanovaccines
Our core technology employs self-assembling nanovaccines customizable for various diseases. These nanovaccines efficiently deliver antigens to immune cells, eliciting stronger and longer-lasting immune responses.
AI-Driven Personalization
Using advanced machine learning algorithms, we develop personalized treatment strategies based on patient-specific immune profiles and tumor characteristics. This ensures highly individualized therapies tailored to each patient’s unique disease progression.
Expanding the Frontiers of Peptide Delivery Technology Research
Our team is continuously advancing diverse lines of investigation to expand our catalogue of active peptides and RNA-based therapeutics, addressing critical biomedical challenges with innovative, high-potential solutions.
ImmuNova BioMed is at the forefront of oncological advancements, delivering groundbreaking solutions in:
Anti-Tumor Immunotherapies: Stimulating targeted immune responses to effectively combat cancer.
Targeted Drug Delivery Systems: Developing advanced platforms for precise, in vivo delivery of drugs and imaging agents, significantly enhancing therapeutic outcomes and diagnostic accuracy.
Our commitment to innovation ensures that we remain leaders in biotechnology, delivering transformative solutions to address the most pressing healthcare challenges.